SCHEMBL1356540

SCHEMBL1356540

COc1cccc(C(=O)OO)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.70
CES2 O00748 1/20 0.69
CES1 P23141 1/20 0.69
ESR1 P03372 1/20 0.63
ESR2 Q92731 1/20 0.63
SMN1; SMN2 Q16637 6/20 0.58
TP53 P04637 2/20 0.58
NPC1 O15118 9/20 0.57
RAB9A P51151 8/20 0.57
TSHR P16473 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
RXFP1 Q9HBX9 1/20 0.56
PRSS1 P07477 1/20 0.55
PRSS2 P07478 1/20 0.55
PRSS3 P35030 1/20 0.55
ABCG2 Q9UNQ0 1/20 0.54
NLRP3 Q96P20 1/20 0.54
ALDH1A1 P00352 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30393680 0.86 CES2 (0.71) PARP1CES2CES1ESR1ESR2
Methyl 3-Methoxybenzoate SCHEMBL384913 0.86 SMN1; SMN2 (0.73) PARP1CES2CES1ESR1ESR2
SCHEMBL447346 0.86 CES2 (0.71) PARP1CES2CES1ESR1ESR2
Methyl 3-Methoxybenzoate SCHEMBL29702092 0.86 SMN1; SMN2 (0.73) PARP1CES2CES1ESR1ESR2
SCHEMBL23509 0.86 CES2 (0.71) PARP1CES2CES1ESR1ESR2
SCHEMBL8190990 0.83 CES2 (0.67) PARP1CES2CES1ESR1ESR2
SCHEMBL28120515 0.83 CES2 (0.67) PARP1CES2CES1ESR1ESR2
SCHEMBL17629345 0.83 PARP1 (0.68) PARP1CES2CES1ESR1ESR2
SCHEMBL27616751 0.83 CES2 (0.67) PARP1CES2CES1ESR1ESR2
SCHEMBL6970519 0.83 CES2 (0.67) PARP1CES2CES1ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0484265-A1 A process for the preparation of omeprazol CENTRO GENESIS PARA LA INVESTIGACION, S.L. (ES) 1992-05-06 EP claimed
WO-2024033288-A1 SALICIN DERIVATIVES AS INHIBITORS OF SGLT2 Société des Produits Nestlé S.A. (CH) 2024-02-15 WO disclosed
WO-2022177313-A1 SESQUITERPENE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF 엠에프씨 주식회사 2022-08-25 WO disclosed
US-20210289794-A1 COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-09-23 US disclosed
US-9431172-B2 Biaxially oriented electrical insulating film BOREALIS TECHNOLOGY OY (FI) 2016-08-30 US disclosed
CN-102762260-A Oral compositions containing extracts of zizyphus joazeiro and related methods COLGATE PALMOLIVE CO 2012-10-31 CN disclosed
CN-102665674-A Oral compositions containing a combination of natural extracts and related methods COLGATE PALMOLIVE CO 2012-09-12 CN disclosed
EP-2440632-A2 LIQUID CRYSTAL COMPOSITIONS E. I. du Pont de Nemours and Company (US) 2012-04-18 EP disclosed
EP-2440631-A1 LIQUID CRYSTAL COMPOSITIONS E. I. du Pont de Nemours and Company (US) 2012-04-18 EP disclosed
US-20110280940-A1 Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy KISS ROBERT (BE) 2011-11-17 US disclosed
EP-0879830-B1 Modified polypropylene having improved processability BOREALIS GMBH (AT) 2002-11-13 EP disclosed
EP-1247837-A2 Modified amino resins for semifinished products and molded bodies having an improved resilience Agrolinz Melamin GmbH (AT) 2002-10-09 EP disclosed
EP-0884355-B1 Polyolefin foams with fine cells BOREALIS GMBH (AT) 2002-07-17 EP disclosed
EP-0884355-A1 Polyolefin foams with fine cells PCD Polymere AG (AT) 1998-12-16 EP disclosed
EP-0884335-A1 Segmented polyolefines PCD Polymere AG (AT) 1998-12-16 EP disclosed
EP-0879844-A1 Polyolefin foams with high resistance against deformation by heat PCD Polymere AG (AT) 1998-11-25 EP disclosed
EP-0879830-A1 Modified polypropylene having improved processability PCD Polymere AG (AT) 1998-11-25 EP disclosed
EP-0878567-A2 Polyolefin fibres and polyolefin yarns and textile materials thereof PCD Polymere AG (AT) 1998-11-18 EP disclosed
EP-0821018-A2 Crosslinkable olefinic polymers and method for their preparation PCD-Polymere Gesellschaft m.b.H. (AT) 1998-01-28 EP disclosed
EP-0787750-A2 Poly(alkylethylene) structural isomers PCD-Polymere Gesellschaft m.b.H. (AT) 1997-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110280940-A1 Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy PSEN2, PSEN1, VHL PARP1 218/4885CES2 2470/4885CES1 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.